Project Grant R35HL183548
- Federal Project Grant Award Summary The University of Pittsburgh received a $1,392,946 Project Grant awarded July 20, 2025, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on obesity-associated asthma through completion April 30, 2029. This research project investigates the mechanistic relationship between gut dysbiosis, microbial-derived metabolites, and airway hyperresponsiveness in obese patients...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...
- Federal Grant Award Summary The University of Pittsburgh received a $791,485 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through May 31, 2029. This award funds research on the treatment of post-infarction cardiac remodeling through the development and validation of ultrasound-targeted microbubble cavitation (UTMC), a theranostic ultrasound-based therapeutic approach. The...
- Federal Grant Award Summary The University of Pittsburgh received a $100,228 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2026, with a completion date of April 30, 2028. This research initiative, titled "Elucidating Mechanisms Regulating Treg Tissue Responses Driven by IL-33 in the Lung," investigates regulatory T cell (Treg) therapy as a potential treatment for acute...
- Federal Grant Award Summary The University of Pittsburgh received a $258,516 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025 through June 30, 2027. This award funds research investigating mitochondrial-derived peptides (MDPs) in chronic obstructive pulmonary disease (COPD), a condition affecting approximately 16 million U.S. adults and representing the sixth leading cause of death...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $300,000 Project Grant on September 15, 2025, for research titled "Real-Time Evaluation of Acute Myocardial Infarction with Multi-Lead ECG Monitoring from Wearable PPG Measurements" under the Cardiovascular Diseases Research program (CFDA 93.837). The award, which extends through June 30, 2029, supports research to develop and validate advanced diagnostic and...
- Federal Grant Award Summary The University of Pittsburgh received a $1,363,729 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for April 30, 2029. This grant supports the development of a minimally invasive surgical system for treating ischemic cardiomyopathy (ICM) through targeted injection of thermoresponsive hydrogels into damaged cardiac tissue. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,519 Project Grant to the University of Pittsburgh effective September 15, 2025, through June 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative investigates the non-canonical roles of NIPBL (Nipped-B-Like protein) in cardiomyocytes to address a critical knowledge gap in understanding cardiac dysfunction in Cornelia de Lange Syndrome (CDLS)....
- The University of Pittsburgh received a $109,076 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with performance occurring in Pittsburgh, Pennsylvania. The award, which commenced on September 10, 2025 and extends through September 9, 2029, supports research activities aligned with NHLBI's mission to advance understanding and treatment of heart, lung, and blood diseases through basic,...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports basic and translational research investigating the role of leucine metabolism in atherosclerosis development. The University of Pittsburgh received $788,863 in obligated funding for the project period from May 1, 2026, through February 28, 2030. The research will deliver scientific outputs focused on manipulating leucine uptake,...
The University of Pittsburgh received a $756,607 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion expected by April 30, 2033. This research initiative investigates lysosomal nutrient-sensing mechanisms in macrophages as a therapeutic approach to atherosclerosis and cardiovascular disease. The research leverages transcription factor EB (TFEB) regulation of autophagy-lysosomal biogenesis, nutrient-mediated mammalian target of rapamycin complex 1 (mTORC1) signaling pathways, and the relationship between dietary protein and lipid composition and macrophage degradative capacity to develop novel interventions for cardiovascular disease prevention and treatment. The award supports a broad research program designed to elucidate mechanistic links between nutrition, lysosomal nutrient-sensing, and macrophage autophagy-lysosomal dysfunction in atherosclerotic plaque formation. Deliverables include scientific discoveries regarding disease mechanisms, identification of novel therapeutic targets for modulating macrophage lipid degradation, characterization of nutrient-sensing regulatory pathways, and potential development of dietary or pharmacological interventions to enhance the autophagy-lysosome system in macrophages. The research extends from basic mechanistic investigation through translational applications, positioning findings to reduce cardiovascular disease morbidity and mortality through improved understanding of cellular processes underlying atherosclerosis progression.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $756.6k | 3/16/26 |